Share Price and Basic Stock Data
Last Updated: January 24, 2026, 4:12 pm
| PEG Ratio | 1.89 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Jyothy Labs Ltd operates within the personal care industry, and its recent financial performance reflects a robust growth trajectory. The company reported sales of ₹2,486 Cr for the fiscal year ending March 2023, up from ₹2,196 Cr in the previous year, marking a year-on-year growth of approximately 13.2%. This positive trend continued into the subsequent fiscal year, with projected sales of ₹2,757 Cr for March 2024 and ₹2,847 Cr for March 2025. Quarterly sales figures indicate consistent growth, with revenues rising from ₹597 Cr in June 2022 to ₹732 Cr in September 2023. The company’s strategic positioning in the personal care segment, combined with effective marketing initiatives, has contributed to this upward trend. Despite challenges in the broader market, Jyothy Labs has managed to increase its market share, highlighting its competitive edge in a sector characterized by intense rivalry.
Profitability and Efficiency Metrics
Jyothy Labs demonstrated strong profitability metrics, with a reported net profit of ₹370 Cr for the fiscal year ending March 2025, maintaining a net profit margin of 13.00%. The operating profit margin (OPM) stood at 17% for the same fiscal year, underscoring the company’s ability to manage its cost structure effectively. The interest coverage ratio (ICR) was an impressive 93.62x, indicating robust earnings relative to interest expenses. This suggests that the company is well-positioned to cover its financial obligations. Additionally, return on equity (ROE) was reported at 19.0%, while return on capital employed (ROCE) was at 24.6%, both of which are favorable compared to typical sector benchmarks. These metrics reflect efficient management and strong operational performance, positioning Jyothy Labs favorably in the competitive landscape.
Balance Sheet Strength and Financial Ratios
The balance sheet of Jyothy Labs showcases a solid financial foundation, with total assets reported at ₹2,691 Cr as of March 2025. The company’s reserves stood at ₹2,013 Cr, demonstrating a healthy accumulation of retained earnings. Notably, borrowings were minimal at ₹61 Cr, reflecting a low debt burden and a total debt-to-equity ratio of 0.00, which is significantly lower than industry averages. The current ratio of 2.76 indicates strong liquidity, suggesting that the company can easily meet its short-term obligations. Furthermore, the price-to-book value ratio (P/BV) was reported at 5.89x, which, while on the higher side, indicates market confidence in the company’s growth potential. Overall, the financial ratios suggest a well-capitalized company with prudent financial management practices.
Shareholding Pattern and Investor Confidence
Jyothy Labs exhibits a robust shareholding structure, with promoters holding a substantial 62.88% stake, which reflects strong internal confidence in the company’s direction. Foreign institutional investors (FIIs) accounted for 12.11% of the shareholding, while domestic institutional investors (DIIs) held 16.08%. This diverse ownership structure is indicative of solid investor confidence, especially as the number of shareholders increased from 1,30,772 in December 2022 to 2,17,305 by March 2025. The gradual increase in public shareholding from 6.63% to 8.91% during the same period further demonstrates an expanding investor base. However, the slight decline in FII participation from a peak of 16.43% in March 2024 to 12.11% in March 2025 raises some concerns regarding foreign investor sentiment, which could impact stock performance if the trend continues.
Outlook, Risks, and Final Insight
Looking ahead, Jyothy Labs appears well-positioned for continued growth, driven by its strong market presence and operational efficiencies. However, potential risks include rising raw material costs and intensified competition, which could pressure margins. Additionally, fluctuations in consumer demand, particularly in discretionary spending, may pose challenges. The company’s focus on innovation and expanding product lines should help mitigate some of these risks. If Jyothy Labs can maintain its operational efficiency and adapt to market trends, it is likely to sustain its growth trajectory. The ongoing commitment to enhancing shareholder value through prudent financial management and strategic investments will be crucial in navigating the evolving landscape of the personal care industry.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Honasa Consumer Ltd | 8,844 Cr. | 272 | 334/190 | 71.1 | 38.8 | 0.00 % | 7.44 % | 5.51 % | 10.0 |
| Ambica Agarbathies Aroma & Industries Ltd | 41.2 Cr. | 24.0 | 37.0/22.3 | 80.8 | 65.2 | 0.00 % | 7.49 % | 0.45 % | 10.0 |
| Ador Multi Products Ltd | 120 Cr. | 125 | 149/23.4 | 32.5 | 0.00 % | 11.4 % | 3.09 % | 10.0 | |
| Kaya Ltd | 561 Cr. | 369 | 488/204 | 60.9 | 0.00 % | 2.50 % | % | 10.0 | |
| Jyothy Labs Ltd | 9,153 Cr. | 249 | 423/244 | 25.0 | 55.8 | 1.40 % | 24.6 % | 19.0 % | 1.00 |
| Industry Average | 71,264.71 Cr | 1,856.86 | 57.37 | 112.70 | 0.79% | 29.21% | 23.91% | 4.94 |
Quarterly Result
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 547 | 597 | 659 | 613 | 617 | 687 | 732 | 678 | 660 | 742 | 734 | 704 | 667 |
| Expenses | 489 | 537 | 579 | 528 | 526 | 570 | 597 | 559 | 552 | 608 | 595 | 589 | 555 |
| Operating Profit | 57 | 60 | 80 | 84 | 91 | 117 | 135 | 119 | 108 | 133 | 138 | 116 | 112 |
| OPM % | 10% | 10% | 12% | 14% | 15% | 17% | 18% | 18% | 16% | 18% | 19% | 16% | 17% |
| Other Income | 6 | 13 | 12 | 15 | 6 | 17 | 13 | 11 | 13 | 14 | 13 | 14 | 11 |
| Interest | 3 | 3 | 3 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| Depreciation | 15 | 13 | 13 | 12 | 12 | 12 | 12 | 13 | 13 | 13 | 14 | 14 | 15 |
| Profit before tax | 45 | 57 | 76 | 84 | 82 | 121 | 135 | 115 | 107 | 132 | 136 | 114 | 107 |
| Tax % | 17% | 16% | 14% | 20% | 28% | 21% | 23% | 21% | 27% | 23% | 23% | 23% | 29% |
| Net Profit | 37 | 48 | 65 | 67 | 59 | 96 | 104 | 91 | 78 | 102 | 105 | 87 | 76 |
| EPS in Rs | 1.03 | 1.32 | 1.76 | 1.84 | 1.61 | 2.62 | 2.84 | 2.48 | 2.13 | 2.77 | 2.86 | 2.38 | 2.08 |
Last Updated: May 31, 2025, 8:43 am
Below is a detailed analysis of the quarterly data for Jyothy Labs Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 667.00 Cr.. The value appears to be declining and may need further review. It has decreased from 704.00 Cr. (Dec 2024) to 667.00 Cr., marking a decrease of 37.00 Cr..
- For Expenses, as of Mar 2025, the value is 555.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 589.00 Cr. (Dec 2024) to 555.00 Cr., marking a decrease of 34.00 Cr..
- For Operating Profit, as of Mar 2025, the value is 112.00 Cr.. The value appears to be declining and may need further review. It has decreased from 116.00 Cr. (Dec 2024) to 112.00 Cr., marking a decrease of 4.00 Cr..
- For OPM %, as of Mar 2025, the value is 17.00%. The value appears strong and on an upward trend. It has increased from 16.00% (Dec 2024) to 17.00%, marking an increase of 1.00%.
- For Other Income, as of Mar 2025, the value is 11.00 Cr.. The value appears to be declining and may need further review. It has decreased from 14.00 Cr. (Dec 2024) to 11.00 Cr., marking a decrease of 3.00 Cr..
- For Interest, as of Mar 2025, the value is 2.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.00 Cr. (Dec 2024) to 2.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Mar 2025, the value is 15.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14.00 Cr. (Dec 2024) to 15.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Mar 2025, the value is 107.00 Cr.. The value appears to be declining and may need further review. It has decreased from 114.00 Cr. (Dec 2024) to 107.00 Cr., marking a decrease of 7.00 Cr..
- For Tax %, as of Mar 2025, the value is 29.00%. The value appears to be increasing, which may not be favorable. It has increased from 23.00% (Dec 2024) to 29.00%, marking an increase of 6.00%.
- For Net Profit, as of Mar 2025, the value is 76.00 Cr.. The value appears to be declining and may need further review. It has decreased from 87.00 Cr. (Dec 2024) to 76.00 Cr., marking a decrease of 11.00 Cr..
- For EPS in Rs, as of Mar 2025, the value is 2.08. The value appears to be declining and may need further review. It has decreased from 2.38 (Dec 2024) to 2.08, marking a decrease of 0.30.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: May 15, 2025, 6:11 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,324 | 1,515 | 1,593 | 1,683 | 1,672 | 1,814 | 1,711 | 1,909 | 2,196 | 2,486 | 2,757 | 2,847 |
| Expenses | 1,170 | 1,350 | 1,370 | 1,428 | 1,415 | 1,532 | 1,460 | 1,594 | 1,948 | 2,170 | 2,277 | 2,347 |
| Operating Profit | 154 | 164 | 223 | 255 | 257 | 282 | 251 | 315 | 248 | 316 | 480 | 500 |
| OPM % | 12% | 11% | 14% | 15% | 15% | 16% | 15% | 16% | 11% | 13% | 17% | 18% |
| Other Income | 8 | 6 | 13 | 10 | 62 | 27 | 16 | -5 | 19 | 47 | 54 | 51 |
| Interest | 55 | 14 | 62 | 56 | 48 | 35 | 33 | 19 | 12 | 13 | 5 | 6 |
| Depreciation | 24 | 33 | 31 | 30 | 31 | 31 | 53 | 56 | 58 | 50 | 50 | 56 |
| Profit before tax | 82 | 125 | 143 | 179 | 241 | 243 | 182 | 235 | 197 | 299 | 479 | 489 |
| Tax % | 1% | 3% | 48% | -14% | 26% | 19% | 10% | 19% | 19% | 20% | 23% | 24% |
| Net Profit | 81 | 121 | 74 | 204 | 179 | 198 | 163 | 191 | 159 | 240 | 369 | 370 |
| EPS in Rs | 2.25 | 3.35 | 2.16 | 5.73 | 5.12 | 5.59 | 4.64 | 5.43 | 4.41 | 6.53 | 10.06 | 10.09 |
| Dividend Payout % | 67% | 60% | 116% | 52% | 5% | 54% | 65% | 74% | 57% | 46% | 35% | 35% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 49.38% | -38.84% | 175.68% | -12.25% | 10.61% | -17.68% | 17.18% | -16.75% | 50.94% | 53.75% | 0.27% |
| Change in YoY Net Profit Growth (%) | 0.00% | -88.23% | 214.52% | -187.93% | 22.87% | -28.29% | 34.85% | -33.93% | 67.70% | 2.81% | -53.48% |
Jyothy Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 11% |
| 3 Years: | 9% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 16% |
| 3 Years: | 32% |
| TTM: | 3% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 19% |
| 3 Years: | 21% |
| 1 Year: | -39% |
| Return on Equity | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 17% |
| 3 Years: | 18% |
| Last Year: | 19% |
Last Updated: September 5, 2025, 8:35 am
Balance Sheet
Last Updated: December 4, 2025, 1:30 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 18 | 18 | 18 | 18 | 18 | 37 | 37 | 37 | 37 | 37 | 37 | 37 |
| Reserves | 716 | 762 | 883 | 1,071 | 1,126 | 1,290 | 1,192 | 1,392 | 1,407 | 1,512 | 1,772 | 2,013 |
| Borrowings | 534 | 569 | 451 | 498 | 544 | 281 | 285 | 117 | 171 | 47 | 51 | 61 |
| Other Liabilities | 386 | 468 | 417 | 266 | 291 | 335 | 323 | 410 | 408 | 466 | 542 | 580 |
| Total Liabilities | 1,654 | 1,817 | 1,770 | 1,853 | 1,979 | 1,942 | 1,836 | 1,956 | 2,023 | 2,062 | 2,401 | 2,691 |
| Fixed Assets | 1,094 | 1,074 | 1,068 | 1,097 | 1,091 | 1,101 | 1,149 | 1,147 | 1,122 | 1,116 | 1,125 | 1,141 |
| CWIP | 4 | 16 | 8 | 9 | 15 | 14 | 24 | 10 | 8 | 15 | 13 | 22 |
| Investments | 61 | 194 | 86 | 28 | 113 | 104 | 0 | 0 | 0 | 0 | 192 | 456 |
| Other Assets | 494 | 533 | 608 | 719 | 760 | 723 | 662 | 799 | 893 | 930 | 1,071 | 1,071 |
| Total Assets | 1,654 | 1,817 | 1,770 | 1,853 | 1,979 | 1,942 | 1,836 | 1,956 | 2,023 | 2,062 | 2,401 | 2,691 |
Below is a detailed analysis of the balance sheet data for Jyothy Labs Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 37.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 37.00 Cr..
- For Reserves, as of Mar 2025, the value is 2,013.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,772.00 Cr. (Mar 2024) to 2,013.00 Cr., marking an increase of 241.00 Cr..
- For Borrowings, as of Mar 2025, the value is 61.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 51.00 Cr. (Mar 2024) to 61.00 Cr., marking an increase of 10.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 580.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 542.00 Cr. (Mar 2024) to 580.00 Cr., marking an increase of 38.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 2,691.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,401.00 Cr. (Mar 2024) to 2,691.00 Cr., marking an increase of 290.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 1,141.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,125.00 Cr. (Mar 2024) to 1,141.00 Cr., marking an increase of 16.00 Cr..
- For CWIP, as of Mar 2025, the value is 22.00 Cr.. The value appears strong and on an upward trend. It has increased from 13.00 Cr. (Mar 2024) to 22.00 Cr., marking an increase of 9.00 Cr..
- For Investments, as of Mar 2025, the value is 456.00 Cr.. The value appears strong and on an upward trend. It has increased from 192.00 Cr. (Mar 2024) to 456.00 Cr., marking an increase of 264.00 Cr..
- For Other Assets, as of Mar 2025, the value is 1,071.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 1,071.00 Cr..
- For Total Assets, as of Mar 2025, the value is 2,691.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,401.00 Cr. (Mar 2024) to 2,691.00 Cr., marking an increase of 290.00 Cr..
Notably, the Reserves (2,013.00 Cr.) exceed the Borrowings (61.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -380.00 | -405.00 | -228.00 | -243.00 | -287.00 | 1.00 | -34.00 | 198.00 | 77.00 | 269.00 | 429.00 | 439.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 18 | 14 | 22 | 25 | 35 | 31 | 26 | 18 | 24 | 20 | 27 | 35 |
| Inventory Days | 91 | 87 | 81 | 80 | 79 | 76 | 91 | 101 | 85 | 77 | 74 | 84 |
| Days Payable | 59 | 62 | 70 | 61 | 63 | 67 | 53 | 69 | 67 | 55 | 72 | 75 |
| Cash Conversion Cycle | 51 | 39 | 32 | 45 | 51 | 40 | 65 | 49 | 41 | 42 | 29 | 45 |
| Working Capital Days | 16 | -32 | -114 | -85 | -87 | -33 | -27 | -8 | -1 | 13 | 40 | 39 |
| ROCE % | 11% | 10% | 15% | 16% | 15% | 17% | 14% | 18% | 13% | 18% | 27% | 25% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 10,212,940 | 0.45 | 306.44 | 9,798,362 | 2025-12-08 04:51:34 | 4.23% |
| Mirae Asset Midcap Fund | 4,943,228 | 0.81 | 148.32 | N/A | N/A | N/A |
| Franklin India Flexi Cap Fund | 4,112,112 | 0.62 | 123.38 | 4,112,112 | 2025-04-22 17:25:29 | 0% |
| Canara Robeco Small Cap Fund | 3,119,812 | 0.72 | 93.61 | 2,521,750 | 2025-12-08 04:51:34 | 23.72% |
| Axis Small Cap Fund | 2,803,873 | 0.31 | 84.13 | 2,803,873 | 2025-04-22 17:25:29 | 0% |
| Canara Robeco Flexi Cap Fund | 2,293,683 | 0.49 | 68.82 | 2,211,183 | 2025-12-08 01:55:25 | 3.73% |
| Franklin India Small Cap Fund | 2,216,504 | 0.49 | 66.51 | 2,716,504 | 2025-12-14 05:37:12 | -18.41% |
| Canara Robeco ELSS Tax Saver Fund | 1,896,100 | 0.62 | 56.89 | 1,756,100 | 2025-12-08 04:51:34 | 7.97% |
| Canara Robeco Equity Hybrid Fund | 1,870,000 | 0.49 | 56.11 | 1,795,000 | 2025-12-08 04:51:34 | 4.18% |
| Franklin India ELSS Tax Saver Fund | 1,723,096 | 0.76 | 51.7 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 10.09 | 10.06 | 6.53 | 4.41 | 5.43 |
| Diluted EPS (Rs.) | 10.09 | 10.06 | 6.53 | 4.41 | 5.43 |
| Cash EPS (Rs.) | 11.62 | 11.42 | 7.89 | 5.92 | 6.71 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 55.81 | 49.30 | 42.24 | 38.20 | 37.87 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 55.81 | 49.30 | 42.24 | 38.20 | 37.87 |
| Revenue From Operations / Share (Rs.) | 77.53 | 75.08 | 67.70 | 59.82 | 51.99 |
| PBDIT / Share (Rs.) | 15.12 | 14.53 | 9.68 | 7.27 | 9.07 |
| PBIT / Share (Rs.) | 13.59 | 13.17 | 8.31 | 5.68 | 7.55 |
| PBT / Share (Rs.) | 13.31 | 13.04 | 8.15 | 5.36 | 6.39 |
| Net Profit / Share (Rs.) | 10.09 | 10.06 | 6.53 | 4.33 | 5.19 |
| NP After MI And SOA / Share (Rs.) | 10.09 | 10.06 | 6.53 | 4.41 | 5.43 |
| PBDIT Margin (%) | 19.50 | 19.35 | 14.29 | 12.15 | 17.44 |
| PBIT Margin (%) | 17.52 | 17.54 | 12.27 | 9.50 | 14.52 |
| PBT Margin (%) | 17.16 | 17.36 | 12.03 | 8.96 | 12.29 |
| Net Profit Margin (%) | 13.00 | 13.39 | 9.64 | 7.24 | 9.98 |
| NP After MI And SOA Margin (%) | 13.01 | 13.40 | 9.64 | 7.37 | 10.44 |
| Return on Networth / Equity (%) | 18.07 | 20.43 | 15.47 | 11.22 | 13.96 |
| Return on Capital Employeed (%) | 22.89 | 25.18 | 18.44 | 13.89 | 18.69 |
| Return On Assets (%) | 13.76 | 15.38 | 11.62 | 8.00 | 10.19 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.08 | 0.08 |
| Asset Turnover Ratio (%) | 1.12 | 1.24 | 1.45 | 1.27 | 1.16 |
| Current Ratio (X) | 2.76 | 2.37 | 1.91 | 1.39 | 1.32 |
| Quick Ratio (X) | 2.12 | 1.78 | 1.16 | 0.81 | 0.73 |
| Inventory Turnover Ratio (X) | 9.31 | 4.25 | 4.32 | 3.81 | 3.18 |
| Dividend Payout Ratio (NP) (%) | 34.69 | 29.81 | 38.29 | 90.68 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 30.12 | 26.26 | 31.67 | 66.72 | 0.00 |
| Earning Retention Ratio (%) | 65.31 | 70.19 | 61.71 | 9.32 | 0.00 |
| Cash Earning Retention Ratio (%) | 69.88 | 73.74 | 68.33 | 33.28 | 0.00 |
| Interest Coverage Ratio (X) | 93.62 | 112.80 | 27.15 | 22.61 | 17.31 |
| Interest Coverage Ratio (Post Tax) (X) | 64.18 | 79.08 | 18.78 | 14.48 | 12.13 |
| Enterprise Value (Cr.) | 11925.68 | 15977.96 | 6732.28 | 5292.85 | 4910.52 |
| EV / Net Operating Revenue (X) | 4.19 | 5.80 | 2.71 | 2.41 | 2.57 |
| EV / EBITDA (X) | 21.48 | 29.95 | 18.94 | 19.83 | 14.75 |
| MarketCap / Net Operating Revenue (X) | 4.24 | 5.86 | 2.82 | 2.47 | 2.63 |
| Retention Ratios (%) | 65.30 | 70.18 | 61.70 | 9.31 | 0.00 |
| Price / BV (X) | 5.89 | 8.93 | 4.53 | 3.75 | 3.52 |
| Price / Net Operating Revenue (X) | 4.24 | 5.86 | 2.82 | 2.47 | 2.63 |
| EarningsYield | 0.03 | 0.02 | 0.03 | 0.02 | 0.03 |
After reviewing the key financial ratios for Jyothy Labs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 10.09. This value is within the healthy range. It has increased from 10.06 (Mar 24) to 10.09, marking an increase of 0.03.
- For Diluted EPS (Rs.), as of Mar 25, the value is 10.09. This value is within the healthy range. It has increased from 10.06 (Mar 24) to 10.09, marking an increase of 0.03.
- For Cash EPS (Rs.), as of Mar 25, the value is 11.62. This value is within the healthy range. It has increased from 11.42 (Mar 24) to 11.62, marking an increase of 0.20.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 55.81. It has increased from 49.30 (Mar 24) to 55.81, marking an increase of 6.51.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 55.81. It has increased from 49.30 (Mar 24) to 55.81, marking an increase of 6.51.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 77.53. It has increased from 75.08 (Mar 24) to 77.53, marking an increase of 2.45.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 15.12. This value is within the healthy range. It has increased from 14.53 (Mar 24) to 15.12, marking an increase of 0.59.
- For PBIT / Share (Rs.), as of Mar 25, the value is 13.59. This value is within the healthy range. It has increased from 13.17 (Mar 24) to 13.59, marking an increase of 0.42.
- For PBT / Share (Rs.), as of Mar 25, the value is 13.31. This value is within the healthy range. It has increased from 13.04 (Mar 24) to 13.31, marking an increase of 0.27.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 10.09. This value is within the healthy range. It has increased from 10.06 (Mar 24) to 10.09, marking an increase of 0.03.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 10.09. This value is within the healthy range. It has increased from 10.06 (Mar 24) to 10.09, marking an increase of 0.03.
- For PBDIT Margin (%), as of Mar 25, the value is 19.50. This value is within the healthy range. It has increased from 19.35 (Mar 24) to 19.50, marking an increase of 0.15.
- For PBIT Margin (%), as of Mar 25, the value is 17.52. This value is within the healthy range. It has decreased from 17.54 (Mar 24) to 17.52, marking a decrease of 0.02.
- For PBT Margin (%), as of Mar 25, the value is 17.16. This value is within the healthy range. It has decreased from 17.36 (Mar 24) to 17.16, marking a decrease of 0.20.
- For Net Profit Margin (%), as of Mar 25, the value is 13.00. This value exceeds the healthy maximum of 10. It has decreased from 13.39 (Mar 24) to 13.00, marking a decrease of 0.39.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 13.01. This value is within the healthy range. It has decreased from 13.40 (Mar 24) to 13.01, marking a decrease of 0.39.
- For Return on Networth / Equity (%), as of Mar 25, the value is 18.07. This value is within the healthy range. It has decreased from 20.43 (Mar 24) to 18.07, marking a decrease of 2.36.
- For Return on Capital Employeed (%), as of Mar 25, the value is 22.89. This value is within the healthy range. It has decreased from 25.18 (Mar 24) to 22.89, marking a decrease of 2.29.
- For Return On Assets (%), as of Mar 25, the value is 13.76. This value is within the healthy range. It has decreased from 15.38 (Mar 24) to 13.76, marking a decrease of 1.62.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.12. It has decreased from 1.24 (Mar 24) to 1.12, marking a decrease of 0.12.
- For Current Ratio (X), as of Mar 25, the value is 2.76. This value is within the healthy range. It has increased from 2.37 (Mar 24) to 2.76, marking an increase of 0.39.
- For Quick Ratio (X), as of Mar 25, the value is 2.12. This value exceeds the healthy maximum of 2. It has increased from 1.78 (Mar 24) to 2.12, marking an increase of 0.34.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 9.31. This value exceeds the healthy maximum of 8. It has increased from 4.25 (Mar 24) to 9.31, marking an increase of 5.06.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 34.69. This value is within the healthy range. It has increased from 29.81 (Mar 24) to 34.69, marking an increase of 4.88.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 30.12. This value is within the healthy range. It has increased from 26.26 (Mar 24) to 30.12, marking an increase of 3.86.
- For Earning Retention Ratio (%), as of Mar 25, the value is 65.31. This value is within the healthy range. It has decreased from 70.19 (Mar 24) to 65.31, marking a decrease of 4.88.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 69.88. This value is within the healthy range. It has decreased from 73.74 (Mar 24) to 69.88, marking a decrease of 3.86.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 93.62. This value is within the healthy range. It has decreased from 112.80 (Mar 24) to 93.62, marking a decrease of 19.18.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 64.18. This value is within the healthy range. It has decreased from 79.08 (Mar 24) to 64.18, marking a decrease of 14.90.
- For Enterprise Value (Cr.), as of Mar 25, the value is 11,925.68. It has decreased from 15,977.96 (Mar 24) to 11,925.68, marking a decrease of 4,052.28.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.19. This value exceeds the healthy maximum of 3. It has decreased from 5.80 (Mar 24) to 4.19, marking a decrease of 1.61.
- For EV / EBITDA (X), as of Mar 25, the value is 21.48. This value exceeds the healthy maximum of 15. It has decreased from 29.95 (Mar 24) to 21.48, marking a decrease of 8.47.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.24. This value exceeds the healthy maximum of 3. It has decreased from 5.86 (Mar 24) to 4.24, marking a decrease of 1.62.
- For Retention Ratios (%), as of Mar 25, the value is 65.30. This value is within the healthy range. It has decreased from 70.18 (Mar 24) to 65.30, marking a decrease of 4.88.
- For Price / BV (X), as of Mar 25, the value is 5.89. This value exceeds the healthy maximum of 3. It has decreased from 8.93 (Mar 24) to 5.89, marking a decrease of 3.04.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.24. This value exceeds the healthy maximum of 3. It has decreased from 5.86 (Mar 24) to 4.24, marking a decrease of 1.62.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.03, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Jyothy Labs Ltd:
- Net Profit Margin: 13%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 22.89% (Industry Average ROCE: 29.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 18.07% (Industry Average ROE: 23.91%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 64.18
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.12
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 25 (Industry average Stock P/E: 57.37)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 13%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Personal Care | Ujala House, Ramkrishna Mandir Road, Mumbai Maharashtra 400059 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. M P Ramachandran | Chairman Emeritus |
| Ms. M R Jyothy | Chairperson & Managing Director |
| Mr. Ravi Razdan | Director |
| Mr. T Ananth Rao | Director - Commercial & Operations |
| Mr. Suresh Balakrishna | Independent Director |
| Ms. Bhumika Batra | Independent Director |
| Mr. Narayanan Subramaniam | Independent Director |
| Mr. Aditya Sapru | Independent Director |
FAQ
What is the intrinsic value of Jyothy Labs Ltd?
Jyothy Labs Ltd's intrinsic value (as of 25 January 2026) is ₹243.38 which is 2.26% lower the current market price of ₹249.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹9,153 Cr. market cap, FY2025-2026 high/low of ₹423/244, reserves of ₹2,013 Cr, and liabilities of ₹2,691 Cr.
What is the Market Cap of Jyothy Labs Ltd?
The Market Cap of Jyothy Labs Ltd is 9,153 Cr..
What is the current Stock Price of Jyothy Labs Ltd as on 25 January 2026?
The current stock price of Jyothy Labs Ltd as on 25 January 2026 is ₹249.
What is the High / Low of Jyothy Labs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Jyothy Labs Ltd stocks is ₹423/244.
What is the Stock P/E of Jyothy Labs Ltd?
The Stock P/E of Jyothy Labs Ltd is 25.0.
What is the Book Value of Jyothy Labs Ltd?
The Book Value of Jyothy Labs Ltd is 55.8.
What is the Dividend Yield of Jyothy Labs Ltd?
The Dividend Yield of Jyothy Labs Ltd is 1.40 %.
What is the ROCE of Jyothy Labs Ltd?
The ROCE of Jyothy Labs Ltd is 24.6 %.
What is the ROE of Jyothy Labs Ltd?
The ROE of Jyothy Labs Ltd is 19.0 %.
What is the Face Value of Jyothy Labs Ltd?
The Face Value of Jyothy Labs Ltd is 1.00.